Quality and Conduct in China: Why Leadership Behaviour Is the Real Differentiator
Suat-Ngoh Toh, Head – Clinical Operations, R&D Solutions, IQVIA Asia Pacific
As China’s share of global clinical trials grows, U.S. sponsors need partners who can deliver volume without compromising quality. Drawing on IQVIA’s operations across China, this article argues that quality outcomes are driven by leadership behaviour - not frameworks alone. Four principles define this approach: leaders owning quality rather than delegating it, a preventive mindset on conduct risk, applying global standards with local intent, and building sponsor trust through transparency and visible presence.
China has become a cornerstone of global clinical development. Regulatory reform, expanding investigator expertise, and the scale of its healthcare system have made the country integral to multinational trials. But as China’s role grows, so does scrutiny around quality, data integrity, and ethical conduct.
For U.S. sponsors expanding into this market, the central question is no longer whether China can deliver volume. It’s whether it can deliver volume without sacrificing the quality standards that global regulatory agencies expect. Those two demands don’t have to be in conflict but whether they coexist depends almost entirely on how operations are led on the ground.
From leading operations across China, one reality is clear: quality outcomes are driven less by frameworks alone and more by leadership behaviours. The difference between compliance on paper and quality in practice lies in how leaders engage, prioritise, and stay present. Four principles are shaping how this is being done.
Quality must be owned by leaders — not delegated
In complex, fast-moving trial environments, quality cannot be treated as a function to be handed off to QA teams. It must be actively owned by leadership.
At IQVIA China, quality is reinforced through an annual, cross-functional quality plan aligned across clinical operations, regulatory, and quality teams. Well-defined workstreams and regular leadership readouts enable timely decision-making, reduce duplication, and maintain focus on shared priorities.
This visible engagement sends a powerful signal to teams and sites alike: quality is not an audit event — it is a leadership commitment embedded in day-to-day execution.
A “Quality First” mindset is deeply ingrained across the organisation. Regardless of role or seniority — from frontline teams to BU leadership quality and compliance remain the primary considerations in how work is planned, executed, and reviewed.
This leadership ownership is further reinforced through the adoption of Lean principles, automation, and emerging AI-enabled capabilities. Lean is applied as a leadership discipline to drive root cause resolution and standardisation of quality critical processes, while automation and AI are applied selectively to simplify workflows, enhance consistency, and support early risk identification. Embedded within the country quality plan, this approach strengthens continuous improvement as well as proactive, data driven insights.
Conduct risk requires a preventive mindset
As clinical trials grow more complex, operational pressure on sites and study teams increases. Without early intervention, these pressures can translate into risks to protocol adherence and data integrity.
A preventive mindset starts at the front line. Targeted CRA quality clinics, experience-sharing through real case studies, and localised risk controls help frontline teams recognise warning signs early. Equally important is a strong understanding of China-specific source documentation environments, including hospital information systems (HIS), which vary widely across institutions.
By strengthening awareness and capability at the front line, potential issues can be identified and addressed before they escalate into audit findings or regulatory concerns.
Given the specific characteristics of the China healthcare environment, IQVIA has maintained close and timely communication with hospital management, particularly the GCP Offices. This has enabled early and proactive alignment on expectations and standards related to risk based monitoring (RBM) implementation and source data management. Such ongoing engagement helps ensure a consistent understanding and shared approach, while respecting local operational realities.
This preventive mindset is further reinforced by Lean-enabled reviews, automation, and AI-supported trend analysis, together with strong regulatory risk awareness. Structured problem-solving, compliance-focused experience sharing, and data-driven insights enable teams to address deviations and inefficiencies at their source — before they manifest as inspection findings, data integrity concerns, or regulatory observations.
Global standards must be applied with local intent
Maintaining global quality standards does not mean applying them uniformly without context. Success in China depends on combining global expectations with a deep understanding of local regulations, guidance, and operational realities.
In China, regulatory compliance is treated as a foundational requirement rather than a downstream check. Global standards are applied through local work instructions that are aligned with evolving regulations, supported by gap assessments and continuous refresh driven by regulatory change. This approach ensures compliance is designed into daily execution, rather than enforced after the fact while preserving consistency with global expectations.
Clear RACI models between CRAs, clinical managers, and sites help reinforce accountability. Practical decision frameworks and close collaboration with site management organisations (SMOs) further support consistent site conduct.
When localisation is done thoughtfully, it strengthens compliance rather than diluting it bridging the gap between what a global protocol requires and what ground-level execution actually looks like in a Chinese hospital network.
Strategic partnerships with sites also support closer interaction with key institutions, allowing for more timely and detailed alignment on industry policy interpretations and shared expectations.
Trust is built through transparency and presence
In a high-growth, high-complexity market, remote governance alone is insufficient. Strong CRA capability, early issue identification and escalation, and close collaboration with sponsors are all essential — but so is visible senior leadership involvement. One of the most common concerns U.S. sponsors raise is that they can’t easily see whether quality is being maintained under delivery pressure. Visible leadership is what makes quality legible from the outside.
When leaders are present — listening, guiding, and acting decisively — teams are more likely to raise concerns early rather than work around them. This transparency fosters a culture where issues are surfaced quickly, addressed collaboratively, and resolved before they affect study integrity.
In performance and KPI management, line managers are closely aligned on leadership accountability, with strong emphasis placed on workload balance and pressure management. By actively addressing employee stress and creating psychological safety, teams are more willing to surface potential risks early enabling more timely escalation and resolution.
“The difference between compliance on paper and quality in practice is leadership — how present leaders are, how early risks are addressed, and how clearly accountability is set.”
— Suat-Ngoh Toh, Head – Clinical Operations, R&D Solutions, IQVIA Asia Pacific
Leadership is the true differentiator
China’s contribution to global clinical development will continue to expand. The question for U.S. sponsors is not whether to be in this market, it’s how to evaluate the partners running their programs within it.
The right question to ask is not whether your China partner has a quality system. Most do. The more revealing question is how their teams behave when the timeline gets tight and whether quality is something leaders own or something they delegate when pressure arrives. At IQVIA, the answer to that question is built into how operations are structured and led across the region.
The leadership behaviours that define quality in China, ownership, prevention, thoughtful localisation, and visible presence are what it looks like when quality is treated as a leadership responsibility, not a regulatory obligation. That distinction is increasingly what separates the partners sponsors trust from the ones they manage.
The innovation spirit and strong sense of professional rigour demonstrated by the China leadership team further safeguard IQVIA’s ability to remain an industry leader in a rapidly changing market, while continuing to deliver the reliability and quality that global development programs demand.
Author Bio
Based in Singapore, Suat‑Ngoh Toh is Regional Head of Clinical Operations, R&D Solutions, Asia at IQVIA, where she provides strategic leadership across Clinical Operations, Quality Management, and Business Operations and Capabilities. She focuses on shaping governance, establishing standardized frameworks, and advancing a forward‑looking quality and risk management agenda through the integration of Lean thinking, data‑driven oversight, and emerging automation and AI‑enabled capabilities. Her work supports scalable excellence, proactive decision‑making, and sustained, high‑quality delivery across complex clinical research portfolios in the Asia Pacific region. With more than 25 years of experience across both the CRO and pharmaceutical sectors, Suat‑Ngoh brings deep expertise in clinical operations, portfolio and program management, and large‑scale trial execution across Asia Pacific and global development programs. Her experience spans multiple therapeutic areas, including oncology, virology, vaccines, cardiovascular disease, metabolism, and infectious diseases. She has held regional leadership roles at IQVIA, PAREXEL, Boehringer Ingelheim, and Novartis, leading regional clinical portfolios, supporting global development programs, and establishing strategic CRO partnerships and governance models. She holds a Master’s degree in Medical Statistics from the London School of Hygiene & Tropical Medicine and a Bachelor of Science in Pharmacy from the National University of Singapore.
